The story of Sildenafil presents a challenging picture for investors. While the initial launch generated substantial gains, the expiration of its intellectual property protection opened the door to off-brand competitors, dramatically eroding market share. This creates a unique challenge for drug manufacturers banking on comparable blockbuster medic

The legacy of Viagra, and its parent company copyright, presents a intriguing case study for investors. Initially a blockbuster drug, yielding billions in income, its intellectual property lapse created a deluge of generic competition , significantly diminishing its dominance. While some firms may seek to capitalize on similar conditions , the curr